Kyverna Therapeutics, Inc. KYTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$156.4M-7.6% | -$161.31M-26.5% | -$160.99M-45.5% | -$158.7M-73.2% | -$145.42M-91.6% | ||
| $1.65M-23.4% | $1.8M-15.7% | $1.99M-1.9% | $2.14M+11.8% | $2.15M+19.9% | ||
| $11.09M+34.6% | $10.08M+20.6% | $8.76M+12.9% | $9.47M+94.7% | $8.24M+104% | ||
| $3.03M— | $543K— | —— | —— | —— | ||
| $35K-98.0% | $5.11M+147% | $2.52M-2.5% | $2.25M+41.8% | $1.72M+135% | ||
| —— | —— | —— | —— | $2.18M+27.5% | ||
| -$2.88M-1.3% | -$3.34M-39.2% | -$3.14M-41.9% | -$2.99M-46.9% | -$2.84M-53.0% | ||
| -$150.39M-12.5% | -$153.71M-34.5% | -$157.25M-64.2% | -$141.41M-78.1% | -$133.64M-101% | ||
| —— | —— | $538K-73.2% | $638K-70.5% | $1.66M+46.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | $24.7M— | $18.53M— | $12.35M— | $6.18M— | ||
| $17.18M+28,264% | $16.94M— | $1.43M+184% | -$134K-119% | -$61K-109% | ||
| $553K-48.5% | $808K-16.2% | $970K+3.6% | $1.09M+21.1% | $1.07M+27.4% | ||
| —— | —— | —— | —— | —— | ||
| $141.48M— | $141.17M— | —— | —— | —— | ||
| -$24.68M— | $27.47M— | —— | —— | —— | ||
| $964K+724% | $415K+192% | $72K-55.6% | $97K-45.8% | $117K-37.4% | ||
| $5.51M-42.0% | $6.89M-10.1% | $7.76M+28.6% | $9.08M+154% | $9.49M+617% | ||
| —— | —— | —— | —— | —— | ||
| —— | -$2.5M— | -$1.88M— | -$1.25M— | -$625K— | ||
| $35K-98.0% | $5.11M+147% | $2.52M-2.5% | $2.25M+41.8% | $1.72M+135% | ||
| -$2.88M-1.3% | -$3.34M-39.2% | -$3.14M-41.9% | -$2.99M-46.9% | -$2.84M-53.0% | ||
| -$2.85M-133% | -$800K-107% | $7.47M+107% | $9.3M+85.3% | $8.67M+252% | ||
| —— | —— | —— | $64K— | -$692K— | ||
| —— | —— | —— | —— | $0— | ||
| $2.82M+3.4% | $2.9M+14.0% | $2.84M+22.6% | $2.78M+33.1% | $2.72M+46.2% | ||
| $553K-48.5% | $808K-16.2% | $970K+3.6% | $1.09M+21.1% | $1.07M+27.4% | ||
| $333K— | $144K— | $94K— | $51K— | —— | ||
| $468K— | $475K— | —— | —— | —— | ||
| —— | $98.97M— | —— | —— | —— | ||
| -$2.88M-1.3% | -$3.34M-39.2% | -$3.14M-41.9% | -$2.99M-46.9% | -$2.84M-53.0% | ||
| $5.44M— | $194K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | -$153.72M-32.0% | -$157.78M-61.4% | -$142.05M-74.2% | -$135.3M-100% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kyverna Therapeutics, Inc. generate?
- Kyverna Therapeutics, Inc. (KYTX) generated -$150.4M in operating cash flow over the trailing twelve months.
- What is Kyverna Therapeutics, Inc.'s free cash flow?
- After $538.0K of capital expenditures, Kyverna Therapeutics, Inc.'s free cash flow was -$153.7M over the trailing twelve months, down 32.0% year over year.
- Where does Kyverna Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.